Glaukos (NYSE:GKOS) Director Sells $1,760,700.00 in Stock

Glaukos Corporation (NYSE:GKOS) Director Aimee Weisner sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $117.38, for a total value of $1,760,700.00. Following the sale, the director owned 18,806 shares of the company’s stock, valued at $2,207,448.28. The trade was a 44.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Glaukos Trading Up 1.7%

Shares of GKOS stock opened at $121.25 on Thursday. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $130.23. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69. The stock’s fifty day moving average is $115.75 and its two-hundred day moving average is $99.63. The firm has a market capitalization of $7.04 billion, a P/E ratio of -37.19 and a beta of 0.70.

Glaukos (NYSE:GKOS) last issued its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The business had revenue of $143.12 million during the quarter, compared to analyst estimates of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. Glaukos’s quarterly revenue was up 35.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.40) earnings per share. Research analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on GKOS shares. Stephens increased their price target on Glaukos from $115.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, January 2nd. Stifel Nicolaus raised their target price on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. UBS Group boosted their price target on shares of Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, December 23rd. William Blair raised shares of Glaukos to a “strong-buy” rating in a report on Friday, January 30th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $165.00 target price on shares of Glaukos in a research note on Wednesday, January 14th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $133.69.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of GKOS. Riverbridge Partners LLC increased its holdings in Glaukos by 41.0% in the 3rd quarter. Riverbridge Partners LLC now owns 569,644 shares of the medical instruments supplier’s stock valued at $46,454,000 after purchasing an additional 165,673 shares during the last quarter. Holocene Advisors LP grew its stake in shares of Glaukos by 40.1% in the second quarter. Holocene Advisors LP now owns 1,045,886 shares of the medical instruments supplier’s stock valued at $108,030,000 after buying an additional 299,118 shares in the last quarter. State of New Jersey Common Pension Fund D raised its holdings in shares of Glaukos by 4.2% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 19,905 shares of the medical instruments supplier’s stock valued at $2,056,000 after buying an additional 800 shares during the period. Baird Financial Group Inc. lifted its stake in Glaukos by 17.7% during the 2nd quarter. Baird Financial Group Inc. now owns 63,379 shares of the medical instruments supplier’s stock worth $6,546,000 after acquiring an additional 9,545 shares in the last quarter. Finally, Public Sector Pension Investment Board boosted its holdings in Glaukos by 14.8% during the 3rd quarter. Public Sector Pension Investment Board now owns 223,708 shares of the medical instruments supplier’s stock valued at $18,243,000 after acquiring an additional 28,866 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.